-
EP3897743
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3897743
| EP3897743 - ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 08.07.2022 Database last updated on 02.11.2024 | |
| Former | Request for examination was made Status updated on 24.09.2021 | ||
| Former | The international publication has been made Status updated on 02.07.2020 | ||
| Former | unknown Status updated on 20.12.2019 | Most recent event Tooltip | 30.08.2024 | New entry: Reply to examination report | Applicant(s) | For all designated states Sapreme Technologies B.V. Antonie van Leeuwenhoeklaan 9 Building A12-1 3721 MA Bilthoven / NL | [2022/44] |
| Former [2022/36] | For all designated states Sapreme Technologies B.V. Antonie van Leeuwenhoeklaan 9 Building A12-1 3721 MA Bilthoven / NL | ||
| For all designated states Charité - Universitätsmedizin Berlin Charitéplatz 1 10117 Berlin / DE | |||
| Former [2021/43] | For all designated states SAPREME TECHNOLOGIES B.V. Professor Bronkhorstlaan 10 G 92 3723 MB Bilthoven / NL | ||
| For all designated states Charité - Universitätsmedizin Berlin Charitéplatz 1 10117 Berlin / DE | Inventor(s) | 01 /
POSTEL, Ruben Yalelaan 62 LSI, Room 2.09 3584 CM Utrecht / NL | 02 /
FUCHS, Hendrik lnstitut für Laboratoriumsmedizin Klinische Chemie und Pathobiochemie Charité - Universitätsmedizin, Berlin Campus Virchow- Klinikum Augustenburger Platz 1 13353 Berlin / DE | [2021/43] | Representative(s) | Nederlandsch Octrooibureau P.O. Box 29720 2502 LS The Hague / NL | [2021/43] | Application number, filing date | 19817672.9 | 09.12.2019 | [2021/43] | WO2019EP84180 | Priority number, date | NL20182022283 | 21.12.2018 Original published format: NL 2022283 | NL20192023468 | 10.07.2019 Original published format: NL 2023468 | NL20192023568 | 25.07.2019 Original published format: NL 2023568 | [2021/43] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020126600 | Date: | 25.06.2020 | Language: | EN | [2020/26] | Type: | A1 Application with search report | No.: | EP3897743 | Date: | 27.10.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 25.06.2020 takes the place of the publication of the European patent application. | [2021/43] | Search report(s) | International search report - published on: | EP | 25.06.2020 | Classification | IPC: | A61K47/68, A61K47/64, A61K47/59, A61P35/00 | [2021/43] | CPC: |
A61K47/6855 (EP,IL,KR,US);
A61K47/6885 (EP,IL,KR,US);
A61K47/549 (IL,KR,US);
A61K47/55 (EP,IL,US);
A61K47/554 (EP,IL,US);
A61K47/593 (IL,KR,US);
A61K47/595 (IL,KR,US);
A61K47/60 (IL,KR,US);
A61K47/64 (IL,KR);
A61K47/6415 (IL,US);
A61K47/642 (IL,US);
A61K47/643 (IL,US);
A61K47/6807 (EP,IL,KR,US);
A61K47/6817 (US);
A61K47/6825 (EP,IL,KR,US);
A61K47/6845 (US);
A61K47/6849 (EP,IL,KR,US);
A61K47/6851 (EP,IL,KR,US);
A61K47/6857 (EP,IL,KR,US);
A61K47/6863 (EP,IL,KR);
A61K47/6889 (US);
A61K47/6911 (KR);
A61P35/00 (EP,IL,KR,US);
C07H15/256 (EP,IL);
C07J63/008 (EP,IL);
C07K16/32 (EP,IL);
C12N15/113 (US);
A61K2039/505 (EP,IL);
A61K2039/507 (EP,IL);
A61K2300/00 (KR);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/43] | Title | German: | ANTIKÖRPER-WIRKSTOFF-KONJUGAT MIT VERBESSERTEM THERAPEUTISCHEM FENSTER | [2021/43] | English: | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | [2021/43] | French: | CONJUGUÉ ANTICORPS-MÉDICAMENT À FENÊTRE THÉRAPEUTIQUE AMÉLIORÉE | [2021/43] | Entry into regional phase | 13.07.2021 | National basic fee paid | 13.07.2021 | Designation fee(s) paid | 13.07.2021 | Examination fee paid | Examination procedure | 20.05.2020 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 13.07.2021 | Examination requested [2021/43] | 13.07.2021 | Date on which the examining division has become responsible | 04.02.2022 | Amendment by applicant (claims and/or description) | 08.07.2022 | Despatch of a communication from the examining division (Time limit: M06) | 28.11.2022 | Reply to a communication from the examining division | 19.04.2024 | Despatch of a communication from the examining division (Time limit: M06) | 29.08.2024 | Reply to a communication from the examining division | Fees paid | Renewal fee | 26.11.2021 | Renewal fee patent year 03 | 29.12.2022 | Renewal fee patent year 04 | 19.12.2023 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | |||